Shares of Ampliphi Biosciences Corp (NYSEAMERICAN:APHB – Get Free Report) traded down 1.2% during trading on Friday. The company traded as low as $3.15 and last traded at $3.25. 102,950 shares were traded during trading, a decline of 88% from the average daily volume of 842,200 shares. The stock had previously closed at $3.29.
Ampliphi Biosciences Price Performance
The stock’s 50-day moving average price is $4.21 and its two-hundred day moving average price is $6.97.
About Ampliphi Biosciences
AmpliPhi Biosciences Corporation was a clinical-stage biotechnology company focused on developing bacteriophage therapies for bacterial infections, particularly infections caused by antibiotic-resistant pathogens. Bacteriophages are naturally occurring viruses that selectively infect and destroy bacteria, offering a potential alternative or complement to conventional antibiotics.
The company developed a proprietary phage-discovery and development platform and advanced product candidates including AP-PA01, an investigational therapy targeting Pseudomonas aeruginosa infections, and AP-SA02, which targeted Staphylococcus aureus.
Further Reading
- Five stocks we like better than Ampliphi Biosciences
- Amazon’s Record Margins Couldn’t Stop the Sell-Off—Here’s Why
- DoorDash’s $17 Billion Bet on Instacart Faces a Long Regulatory Road Ahead
- FTC Puts A Wrinkle In the Cintas and UniFirst Merger
- Breaching the Valuation: The Real Reason Fortinet Dropped
Receive News & Ratings for Ampliphi Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampliphi Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
